ZTEK Zentek Ltd.
Price Chart
Executive Summary
Zentek subsidiary Triera Biosciences completed a government-funded project on H5N1 avian flu and secured a new $300,000 OCI grant to advance development of a seasonal influenza treatment candidate. The funding is matched between OCI and Zentek and supports ongoing R&D with McMaster University.
Actionable Insight
The news validates progress in Triera’s aptamer platform but represents incremental R&D advancement rather than a commercial milestone. Traders should monitor for future clinical candidate selection or regulatory progress. The matched funding reduces near-term cash burden on Zentek.
Key Facts
- Triera Biosciences completed an Innovative Solutions Canada (ISC) contract focused on H5N1 avian influenza.
- Triera secured a new $300,000 Collaborate 2 Commercialize (C2C) agreement with Ontario Centres of Innovation (OCI), with matched funding from OCI and Zentek.
- The new program targets development of proprietary seasonal influenza treatment candidates using Triera's aptamer platform.
- Work will be conducted in collaboration with Li and Miller Laboratories at McMaster University.
- The platform demonstrated rapid aptamer selection in ~7 weeks for H5N1, showcasing speed advantages over traditional antibody methods.
Financial Impact
The total project budget is $300,000 with matched cash contributions from OCI and Zentek, implying a $150,000 direct cash outlay for Zentek. No material revenue or profit impact is expected in the near term.
Risk Factors
- Early-stage biotech risk: The technology remains in preclinical development with no guarantee of clinical or commercial success.
- Dilution risk: Future capital raises may be needed to fund later-stage development, potentially diluting shareholders.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001062993-26-001997 |
| Document: form6k.htm | 0001062993-26-001997 |
| Document: 0001062993-26-001997-index-headers.html | 0001062993-26-001997 |
| Document: 0001062993-26-001997-index.html | 0001062993-26-001997 |
| Document: 0001062993-26-001997.txt | 0001062993-26-001997 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
6-K
| $0.4848 awaiting T+5 | awaiting T+5 | — | $0.4900 (+1.07%) |
|
May 27, 2026
13d ago
|
6-K
| $0.5900 $0.5600 | ▲ +5.08% | ▲ +6.29% | $0.4900 (+16.95%) |
|
May 13, 2026
27d ago
|
6-K
| $1.01 $0.7300 | ▼ −27.72% | ▼ −26.56% | $0.4900 (−51.49%) |
|
Apr 28, 2026
6w ago
|
6-K
| $0.4500 $0.5000 | ▲ +11.11% | ▲ +9.42% | $0.4900 (+8.89%) |
|
Apr 22, 2026
6w ago
|
6-K
| $0.5000 $0.4315 | ▼ −13.70% | ▼ −13.75% | $0.4900 (−2.00%) |
|
Apr 16, 2026
7w ago
|
6-K
| $0.4900 $0.4700 | ▼ −4.08% | ▼ −4.64% | $0.4900 (+0.00%) |
|
Apr 15, 2026
7w ago
|
6-K
| $0.4800 $0.5000 | ▲ +4.17% | ▲ +2.53% | $0.4900 (+2.08%) |
|
Apr 13, 2026
8w ago
|
6-K
| $0.5400 $0.5000 | ▼ −7.41% | ▼ −10.70% | $0.4900 (−9.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access